Motif Bio Plc (LON: MTFB, NASDAQ:MTFB) chief executive Graham Lumsden hailed as a “significant achievement” the successful completion of a phase III clinical trial of its next-generation antibiotic, iclaprim.
The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections (ABSSSI).
The top-line results revealed it scored well against one of the leading products, vancomycin, on two counts.
Researchers were assessing whether iclaprim was ‘non-inferior’ to vancomycin in the 48 to 72 hours after the start of administration and at the test of cure, a week to a fortnight after patients stop receiving treatment. It also did well in meeting several secondary ‘endpoints’, investors were told.
Kidney disease boost
Data from REVIVE-2, the second phase III trial, which uses an identical protocol but has different trial centres, are expected in the second half of the year.
Motif plans to make a new drug application in the first half of 2018.
It is thought iclaprim could be an important treatment for patients with ABSSSI who may have kidney disease – which is around a quarter of the 3.6mln annually that catch the infection.
"The successful completion of REVIVE-1 is a significant achievement for Motif Bio. I would like to thank the patients and physicians that participated in this important study,” said CEO Lumsden.